Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...

Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...

A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its ...